Business
Stoke Therapeutics, Inc.: Our strategy We are using our proprietary RNA therapeutics platform to create ASOs for the treatment of severe diseases.
Revenue increased 404.5% to $184.4M, while Net income increased 92.3% to ($6.9M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $184.4MWatch
- Profitability — Net income ($6.9M)Watch
- Cash generation — Free cash flow $44.9MOK
- Accounting — Formula-grey distress score · manipulation flag raised · earnings quality safeWatch
- Insiders — 0 buys; 48 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as Stoke Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- IP License$150.8M
- Global Development Activity$17.5M
- License$11.5M
- Service$4.6M
Leadership changes
From Stoke Therapeutics, Inc.'s own filings, the day they're filed.
- Ian F. Smith · Chief Executive Officer · appointmenteff. 2025-10-06
- Huw Nash · Chief Operating Officer · departureeff. 2024-06-18
- Thomas Leggett · Chief Financial Officer · appointmenteff. 2024-05-07
Latest filings
- 8-K · Company announcement2026-08-03
- 10-Q · Quarterly report2026-08-03
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-06-30
- 8-K · Company announcement2026-06-04
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Stoke Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.